nach oben

Erschienen in:

12.09.2022 | Herzinsuffizienz | CME

Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2)

Therapie von Komorbiditäten

verfasst von: Prof. Dr. Dr. med. Stephan von Haehling, Michael Arzt, Wolfram Doehner, Frank Edelmann, Ruben Evertz, Nicole Ebner, Christoph Herrmann-Lingen, Tania Garfias-Veitl, Michael Koziolek, Michel Noutsias, P. Christian Schulze, Rolf Wachter, Gerd Hasenfuß, Ulrich Laufs

Erschienen in: Die Kardiologie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Ziel dieses dreiteiligen Übersichtsbeitrags ist es, anhand der Aspekte leitliniengerechte Arzneimitteltherapie, Behandlung von Komorbiditäten und des körperlichen Trainings Möglichkeiten aufzuzeigen, die zum Erhalt der Mobilität und der Lebensqualität bei Patienten mit Herzinsuffizienz geeignet sind. Im hier vorliegenden zweiten Teil diskutieren wir, dass intravenöse Eisencarboxymaltose bei Patienten mit Eisenmangel Lebensqualität und körperliche Belastbarkeit verbessern kann. Kleine Studien weisen darauf hin, dass Testosteron bei hochselektierten Patienten mit geringer Muskelmasse hilfreich sein könnte. Für SGLT-2(Natrium-Glukose-Co-Transporter 2)-Hemmer liegen erste positive Daten für Patienten mit HFrEF („heart failure with reduced ejection fraction“) und HFpEF („heart failure with preserved ejection fraction“) vor. Die interventionelle Pulmonalvenenisolation zur Wiederherstellung des Sinusrhythmus kann bei Patienten mit Vorhofflimmern und Herzinsuffizienz positive Effekte auf die Belastbarkeit haben. Die Therapie anderer Komorbiditäten der Herzinsuffizienz wie etwa von schlafbezogenen Atmungsstörungen, Diabetes mellitus, chronischer Niereninsuffizienz oder Depression zeigte zwar Verbesserungen der Belastbarkeit und/oder der Lebensqualität, die Aussagekraft der verfügbaren Daten bleibt aber begrenzt.

Nur mit Berechtigung zugänglich

von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, Herrmann-Lingen C, Garfias Macedo T, Koziolek M, Noutsias M, Schulze PC, Wachter R, Hasenfuß G, Laufs U (2021) Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail 23:92–113CrossRef

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli FM, Price S, Rosano GMC, Ruschitzka F, Skibelund KA, ESC Scientific Document Group (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef

von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, Herrmann-Lingen C, Garfias-Veitl T, Koziolek M, Noutsias M, Schulze PC, Wachter R, Hasenfuß G, Laufs U (2022) Erhalt von Leistungsfähigkeit and Lebensqualität bei chronischer Herzinsuffizienz. Kardiologe 16:185–196CrossRef

Roy D, Talajic M, Nattel S et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677PubMedCrossRef

Suman-Horduna I, Roy D, Frasure-Smith N et al (2013) Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 61:455–456PubMedCrossRef

Torp-Pedersen C, Møller M, Bloch Thomsen PE et al (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857–865PubMedCrossRef

Khan MN, Jais P, Cummings J et al (2008) Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359:1778–1785PubMedCrossRef

Di Biase L, Mohanty P, Mohanty S et al (2016) Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133:1637–1644PubMedCrossRef

Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D, CASTLE-AF Investigators (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378:417–427PubMedCrossRef

10.

Ma Y, Bai F, Qin F, Li Y, Tu T, Sun C, Zhou S, Liu Q (2018) Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 18:165PubMedPubMedCentralCrossRef

11.

Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC (2015) Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3:136–145PubMedCrossRef

12.

Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27:699–703PubMedCrossRef

13.

MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, CHARM Investigators (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385PubMedCrossRef

14.

Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, Petrie JR, Struthers AD, Lang CC (2012) The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 14:1303–1310PubMedCrossRef

15.

Núñez J, Palau P, Domínguez E, Mollar A, Núñez E, Ramón JM, Miñana G, Santas E, Fácila L, Górriz JL, Sanchis J, Bayés-Genís A (2018) Early effects of empagliflozin on exercise tolerance in patients with heart failure: a pilot study. Clin Cardiol 41:476–480PubMedPubMedCentralCrossRef

16.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128PubMedCrossRef

17.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357PubMedCrossRef

18.

https://esc365.escardio.org/vgn-ext-templating/Congress/ESC-CONGRESS-2019/Hot-Line-Session-1/204417-dapa-hf-the-dapagliflozin-and-prevention-of-adverseoutcomes-in-heart-failure-trial#video. Zugegriffen: 19. Sept. 2019

19.

Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB (2010) Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled Studie of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 16:111–117PubMedCrossRef

20.

Nielsen R, Wiggers H, Thomson HH, Bovin A, Refsgaard J, Abrahamsen J, Møller N, Bøtker HE, Nørrelund H (2016) Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Res Care 4:e202PubMedPubMedCentralCrossRef

21.

Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research Network (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical study. JAMA 316:500–508PubMedPubMedCentralCrossRef

22.

Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ (2016) Effects of the novel long-acting GLP‑1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 4:559–566PubMedCrossRef

23.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMedCrossRef

24.

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27(11):1954–1960PubMedPubMedCentralCrossRef

25.

Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Wranicz KJ, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD (2021) Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 42:700–710PubMedCrossRef

26.

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ, EMPA-TROPISM (ATRU-4) Investigators (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. j Am Coll Cardiol 77(3):243–255PubMedCrossRef

27.

Arzt M, Woehrle H, Oldenburg O, Graml A, Suling A, Erdmann E, Teschler H, Wegscheider K (2016) Prevalence and predictors of sleep-disordered breathing in patients with stable chronic heart failure: the SchlaHF registry. JACC Heart Fail 4:116–125PubMedCrossRef

28.

Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 42:1203–1212PubMedPubMedCentralCrossRef

29.

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143:326–336PubMedCrossRef

30.

Khayat R, Jarjoura D, Porter K, Sow A, Wannemacher J, Dohar R, Pleister A, Abraham WT (2015) Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. Eur Heart J 36:1463–1469PubMedPubMedCentralCrossRef

31.

Arzt M, Oldenburg O, Graml A, Erdmann E, Teschler H, Wegscheider K, Suling A, Woehrle H (2017) Phenotyping of sleep-disordered breathing in patients with chronic heart failure with reduced ejection fraction-the SchlaHF registry. J Am Heart Assoc 6(12):e5899PubMedPubMedCentralCrossRef

32.

Geib T, Plappert N, Roth T, Popp R, Birner C, Maier LS, Pfeifer M, Arzt M (2015) Prevalence of sleep-disordered breathing-related symptoms in patients with chronic heart failure and reduced ejection fraction. Can J Cardiol 31:839–845PubMedCrossRef

33.

Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O (2011) Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestiveheart failure. Eur Heart J 32:61–74PubMedCrossRef

34.

Wang H, Parker JD, Newton GE, Floras JS, Mak S, Chiu KL, Ruttanaumpawan P, Tomlinson G, Bradley TD (2007) Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 49:1625–3111PubMedCrossRef

35.

Fox H, Bitter T, Sauzet O, Rudolph V, Oldenburg O (2020) Automatic positive airway pressure for obstructive sleep apnea in heart failure with reduced ejection fraction. Clin Res Cardiol 110(7):983–992PubMedPubMedCentralCrossRef

36.

Bradley TD, Logan AG, Kimoff RJ, Sériès F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanly P, Smilovitch M, Tomlinson G, Floras JS, CANPAP Investigators (2005) Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353:2025–2033PubMedCrossRef

37.

Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT (2004) Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 169:361–366PubMedCrossRef

38.

Smith LA, Vennelle M, Gardner RS, McDonagh TA, Denvir MA, Douglas NJ, Newby DE (2007) Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive sleep apnoea: a randomized placebo-controlled trial. Eur Heart J 28:1221–1227PubMedCrossRef

39.

Hall AB, Ziadi MC, Leech JA, Chen SY, Burwash IG, Renaud J, deKemp RA, Haddad H, Mielniczuk LM, Yoshinaga K, Guo A, Chen L, Walter O, Garrard L, DaSilva JN, Floras JS, Beanlands RS (2014) Effects of short-term continuous positive airway pressure on myocardial sympathetic nerve function and energetics in patients with heart failure and obstructive sleep apnea: a randomized study. Circulation 130:892–901PubMedCrossRef

40.

Kasai T, Usui Y, Yoshioka T, Yanagisawa N, Takata Y, Narui K, Yamaguchi T, Yamashina A, Momomura SI, JASV Investigators (2010) Effect of flow-triggered adaptive servoventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 3:140–148PubMedCrossRef

41.

Arzt M, Schroll S, Series F, Lewis K, Benjamin A, Escourrou P, Luigart R, Kehl V, Pfeifer M (2013) Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial. Eur Respir J 42:1244–1254PubMedCrossRef

42.

Hetzenecker A, Escourrou P, Kuna ST, Series F, Lewis K, Birner C, Pfeifer M, Arzt M (2016) Treatment of sleep apnea in chronic heart failure patients with auto-servo ventilation improves sleep fragmentation: a randomized controlled trial. Sleep Med 17:25–31PubMedCrossRef

43.

Randerath WJ, Nothofer G, Priegnitz C, Anduleit N, Treml M, Kehl V, Chest GW (2012) Long-term auto-servoventilation or constant positive pressure in heart failure and coexisting central with obstructive sleep apnea. Chest 142:440–447PubMedCrossRef

44.

Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H (2015) Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 373:1095–1105PubMedPubMedCentralCrossRef

45.

Harrington D, Anker S, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats AJ (1997) Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 30:1758–1764PubMedCrossRef

46.

Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, Anker SD, von Haehling S (2013) Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 34:512–519PubMedCrossRef

47.

Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Maleki M, Malek H, Naderi N (2017) Muscle wasting in young patients with dilated cardiomyopathy. J cachexia sarcopenia muscle 8:542–548PubMedPubMedCentralCrossRef

48.

Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, Loncar G, Springer J, Doehner W, Lainscak M, Hasenfuß G, Anker SD, von Haehling S (2018) Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur J Heart Fail 20:1580–1587PubMedCrossRef

49.

von Haehling S, Garfias Macedo T, Valentova M, Anker MS, Ebner N, Bekfani T, Haarmann H, Schefold JC, Lainscak M, Cleland JGF, Doehner W, Hasenfuss G, Anker SD (2020) Muscle wasting as an independent predictor of survival in patients with chronic heart failure. J cachexia sarcopenia muscle 11(5):1242–1249CrossRef

50.

Bielecka-Dabrowa A, Ebner N, Dos SMR, Ishida J, Hasenfuss G, von Haehling S (2020) Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail 22(12):2314–2326PubMedCrossRef

51.

Miller MS, VanBuren P, LeWinter MM, Braddock JM, Ades PA, Maughan DW, Palmer BM, Toth MJ (2010) Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibers from humans. J Physiol 588:4039–4053PubMedPubMedCentralCrossRef

52.

Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, Wilson JR (1989) Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation 80:1338–1346PubMedCrossRef

53.

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD (2019) Iron deficiency in heart failure: an overview. JACC Heart Fail 7:36–46CrossRef

54.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P (2011) Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 17:899–906PubMedCrossRef

55.

von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD (2015) Iron deficiency and cardiovascular disease. Nat Rev Cardiol 12(11):659–669CrossRef

56.

Fitzsimons S, Yeo TJ, Ling LH, Sim D, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Poppe K, Lund M, Devlin G, Troughton R, Lam CSP, Richards AM, Doughty RN (2021) Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Fail 8(6):4572–4583PubMedPubMedCentralCrossRef

57.

Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La RHP, Henkens MTHM, Weerts J, Spanjers MHA, Knackstedt C, van Empel VPM (2021) Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail 8(2):1304–1313PubMedPubMedCentralCrossRef

58.

González-Costello J, Comín-Colet J, Lupón J, Enjuanes C, de Antonio M, Fuentes L, Moliner-Borja P, Farré N, Zamora E, Manito N, Pujol R, Bayés-Genis A (2018) Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. BMC Cardiovasc Disord 18(1):206PubMedPubMedCentralCrossRef

59.

Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665PubMedCrossRef

60.

Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency: FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51:103–112PubMedCrossRef

61.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448PubMedCrossRef

62.

Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N (2013) IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 168:3439–3442PubMedCrossRef

63.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36:657–668PubMedCrossRef

64.

van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136:1374–1383PubMedPubMedCentralCrossRef

65.

Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF investigators (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895–1904PubMedCrossRef

66.

Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Filippatos G, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Friede T, Fabien V, Dorigotti F, Pocock S, Ponikowski P, on behalf of the AFFIRM-AHF investigators. (2021) The effect of intravenous ferric carboxymaltose on health-related quality of life in iron deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J 42(31):3011–3020CrossRef

67.

Toblli JE, Lombraña A, Duarte P, Di Gennaro F (2007) Intravenous Iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665PubMedCrossRef

68.

van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A, EFFECT-HF Investigators (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136:1374–1383PubMedPubMedCentralCrossRef

69.

Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ (2006) Depression in heart failure—a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48:1527–1537PubMedCrossRef

70.

Herrmann-Lingen C (2018) Chronische Herzinsuffizienz und Depression. Internist 59:445–452PubMedCrossRef

71.

Herrmann-Lingen C (2014) Herzinsuffizienz und Herztransplantation. In: Herrmann-Lingen C, Albus C, Titscher G (Hrsg) Psychokardiologie – Ein Praxisleitfaden für Ärzte und Psychologen, 2. Aufl. DeutscherÄrzteverlag, Köln, S 184–200

72.

Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA (2017) Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and metaanalysis. Heart Fail Rev 22:731–741PubMedPubMedCentralCrossRef

73.

Freedland KE, Carney RM, Rich MW, Steinmeyer BC, Rubin EH (2015) Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical study. JAMA Intern Med 175:1773–1782PubMedPubMedCentralCrossRef

74.

Blumenthal JA, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, Kraus W, Gottlieb S, Blackburn G, Swank A, Whellan DJ (2012) Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA 308:465–474PubMedPubMedCentral

75.

O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R, SADHART-CHF Investigators (2010) Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 56:692–699PubMedPubMedCentralCrossRef

76.

Xiong GL, Fiuzat M, Kuchibhatla M, Krishnan R, O’Connor CM, Jiang W, SADHART-CHF Investigators (2012) Health status and Depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. Circ Heart Fail 5:688–692PubMedPubMedCentralCrossRef

77.

Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Böhm M, Faller H, Deckert J, Ertl G, MOOD-HF Study Investigators and Committee Members (2016) Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA 315:2683–2693PubMedCrossRef

78.

Scherer M, Düngen HD, Inkrot S, Tahirović E, Lashki DJ, Apostolović S, Edelmann F, Wachter R, Loncar G, Haverkamp W, Neskovic A, Herrmann-Lingen C (2013) Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). Eur J Intern Med 24:333–338PubMedCrossRef

79.

He W, Zhou Y, Ma J, Wei B, Fu Y (2020) Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev 25(6):919–926PubMedCrossRef

80.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC National Cardiac Societies, ESC Scientific Document Group (2021) ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227–3337PubMedCrossRef

81.

Ladwig KH, Baghai TC, Doyle F, Hamer M, Herrmann-Lingen C, Kunschitz E, Lemogne C, Beresnevaite M, Compare A, von Känel R, Sager HB, Kop WJ (2022) Mental health-related risk factors and interventions in patients with heart failure: a position paper endorsed by the Euro-pean Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 29(7):1124–1141PubMedCrossRef

82.

Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT (2008) Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 155:751.e1–751.e7CrossRef

83.

Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American heart association. Circulation 139:e840–e878PubMedCrossRef

84.

Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M (2010) Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007613.pub2CrossRefPubMed

85.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, RED-HF Committees, RED-HF Investigators (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368:1210–1219PubMedCrossRef

86.

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomaticheart failure and anemia. Circulation 117:526–535 (Studie of Anemia in Heart Failure Studie (STAMINA-HeFT) Gruppe)PubMedCrossRef

87.

Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, Kremastinos DT (2008) Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 15:365–369PubMedCrossRef

88.

van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P (2007) Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28:2208–2216PubMedCrossRef

89.

Ponikowski P, Anker SD, Szachniewicz J, Okonko DO, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats JS, McDonald K (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49:753–762PubMedCrossRef

90.

Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, Campagna SM, Nuti R (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B‑type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152(1096):e9–e15

91.

Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107:294–299PubMedCrossRef

92.

Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775–1780PubMedCrossRef

Titel: Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2)
Therapie von Komorbiditäten
verfasst von: Prof. Dr. Dr. med. Stephan von Haehling
Michael Arzt
Wolfram Doehner
Frank Edelmann
Ruben Evertz
Nicole Ebner
Christoph Herrmann-Lingen
Tania Garfias-Veitl
Michael Koziolek
Michel Noutsias
P. Christian Schulze
Rolf Wachter
Gerd Hasenfuß
Ulrich Laufs
Publikationsdatum: 12.09.2022
Verlag: Springer Medizin
Schlagwörter: Herzinsuffizienz
Diabetes und Herz
Affektive Störungen
Affektive Störungen
Schlafbezogene Atmungsstörung
6-Minuten-Gehtest
Eisenmangel
Testosteron
Erschienen in: Die Kardiologie / Ausgabe 5/2022
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-022-00574-0

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Schrittmacher- und kardiale Resynchronisationstherapie

Trikuspidalklappeninsuffizienz

Ausdauersport und AV-Block III°

Sachkunde Interventionelle Echokardiographie

Differenzierung von DCM-Subtypen mittels Herz-MRT und Machine Learning

Rezidivierendes Herzrasen bei 19-Jähriger – nur die "Psyche"?

Praxisempfehlungen der Deutschen Diabetes Gesellschaft